Peptide research, quality, and regulatory news.
A review in Frontiers in Bioinformatics surveys how big data, modeling and AI are advancing computational antimicrobial peptide (AMP) discovery — a methods-focused look at the research.
FDA briefing documents recommend against adding BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon to the 503A compounding list before the July 23–24 PCAC meeting.
Retatrutide’s first Phase 3 type 2 diabetes trial, TRANSCEND-T2D-1, was published in The Lancet and presented with TRIUMPH-1 obesity data at ADA 2026.
Researchers at Kyushu University report a coumarin-tag method in Analytical Chemistry that improves accurate de novo sequencing of short peptides by mass spectrometry.
As scrutiny of research-peptide quality grows, one principle keeps surfacing: a Certificate of Analysis (COA) is only meaningful when it is tied to the exact batch in hand and reports more than a single purity figure. A useful COA generally documents several things together: identity confirmation (commonly by mass spectrometry), purity (typically by HPLC), and…
A peer-reviewed study in the International Journal of Obesity compares three GLP-1–class peptides — semaglutide, tirzepatide, and retatrutide — in a genetic mouse model of obesity. The researchers used MC4R-knockout mice, which lack a receptor central to the brain’s appetite-regulating melanocortin pathway and develop obesity, insulin resistance, and markers of liver stress. Over a 21-day…
Eli Lilly has reported topline results from TRIUMPH-1, the first Phase 3 obesity trial of the triple-agonist peptide retatrutide. Retatrutide acts on three receptors — GLP-1, GIP, and glucagon — distinguishing it from single- and dual-agonist compounds in the same class. According to the company’s announcement, mean body-weight reduction rose with dose: roughly 19% at…
Several procedural deadlines for the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides fall within the next few weeks. The committee is scheduled to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, in their free-base and acetate forms — should be eligible for compounding under…
The FDA’s public comment window on whether to keep three popular GLP-1 medicines off the 503B bulk drug substances list closes June 29, 2026. In an April 30, 2026 proposal, the FDA said it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances, given that FDA-approved versions…
The FDA’s Pharmacy Compounding Advisory Committee will review BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon for the 503A compounding bulks list.
